AMT, Janssen Biotech Enter Research and License Pact

Applied Molecular Transport (AMT) has entered into a research collaboration and license agreement granting Janssen Biotech an exclusive, worldwide license for an orally administered biopharma candidate engineered for the treatment of inflammatory bowel diseases. AMT’s technology, TRANSINT, enables the development of oral biopharmaceuticals and RNA therapeutics for local gastrointestinal targeting or systemic release.
 
AMT is eligible to receive upfront license fees, support for research activities conducted in collaboration with Janssen, and development, regulatory and commercialization milestones, plus royalties on sales.
 
“The gastrointestinal submucosa is a region rich in immune targets that modulate local and systemic diseases, including inflammation,” said Tahir Mahmood, Ph.D., founder and chief business officer at Applied Molecular Transport. “The role of molecular trafficking technologies as engines for the development of next-generation, orally administered biopharmaceuticals has been recognized as a significant area of opportunity in the pharmaceutical industry. We are excited to collaborate with Janssen to advance this important platform strategy and program.”